Roche bid for Avastin follow-on suffers blow with trial failure

ZURICH (Reuters) - Swiss drugmaker Roche's bid to follow its blockbuster cancer drug Avastin with a newer, better drug took a hit when it announced on Thursday that an investigational therapy had failed in a study against metastatic colorectal cancer (mCRC).